<DOC>
	<DOCNO>NCT01157156</DOCNO>
	<brief_summary>The primary objective evaluate safety tolerability single repeat administration escalate dos NV1FGF administer intramuscularly patient severe Peripheral Artery Occlusive Disease ( PAOD ) , ( Rutherford 's Grade II , category 4 Grade III , category 5 6 ) . Secondary objective : - To determine biological activity NV1FGF collateral artery development . - To evaluate activity NV1FGF hemodynamic clinical parameter .</brief_summary>
	<brief_title>Safety Tolerability NV1FGF Patients With Severe Peripheral Artery Occlusive Disease</brief_title>
	<detailed_description>Screening period 30 day dose . Patients receive single administration repeat ( 2 ) administration ( 2-week interval ) NV1FGF . Patients follow period 6 month</detailed_description>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>Inclusion criterion : Severe PAOD define Rutherford 's Grade II , category 4 Grade III , category 5 6 Pain rest least 2 week duration and/or trophic lesion least previous 14 day sign heal ( reduction ulcer size depth ) Objective evidence peripheral vascular disease ( rest Ankle Brachial Index &lt; 0.4 and/or rest Toe Brachial Index &lt; 0.3 and/or metatarsal Peripheral Vascular Resistance flat barely pulsatile diseased limb 2 consecutive examination perform least 2 week apart ) Angiographic demonstration total occlusion affect limb one iliac , superficial femoral , popliteal and/or one infrapopliteal arteries Poor candidate surgical intervention revascularization procedure ( tibial artery incontinuity define midleg distance foot autologous tissue available ) Exclusion criterion : Previous current history malignant disease . Patients successful tumor resection 10 year prior inclusion study recurrence patient curatively resect basal/squamous cancer skin allow inclusion Abnormal chest Xray suspect malignant tumor presence Positive stool hemoccult ( expect due hemorrhoid ) Positive Prostate Specific Antigen men suspect malignant tumor presence Abnormal mammography woman suspect malignant tumor presence Papanicolaou smear ( woman ) Class IV Class V characterization Proliferative retinopathy The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>